期刊文献+

晚期膀胱癌患者血清CA19-9测定的临床意义 被引量:4

Clinical Significance of Elevating Serum CA19-9 in Patients with Advanced Bladder Cancer
原文传递
导出
摘要 目的:探讨晚期膀胱癌患者血清CA19-9检测的临床意义。方法:采用电化学发光法测定41例晚期膀胱癌患者外周血CA19-9水平,并对其临床意义进行分析。结果:本组患者CA19-9测定值为(77.1±194.3)IU/ml,其中CA19-9阳性19例,阳性率为46.3%;对照组CA19-9测定值为(13.6±5.2)IU/ml,阳性率为0,两组相比差异有显著统计学意义(P<0.01)。病理检查证实淋巴结转移的11例患者CA19-9阳性率为54.5%,阴性组为14.2%,两组相比差异有统计学意义(P<0.05)。6例远处器官转移的患者中有5例CA19-9阳性,阳性率为83.3%,与无远处转移的患者相比,阳性率差异有统计学意义(P<0.05)。41例患者随访3~46个月,CA19-9阳性组、阴性组3年生存率分别为52.1%和85.9%,差异有统计学意义(P=0.036).036)。结论:血清CA19-9水平与肿瘤的进展以及预后密切相关,可能是判断晚期膀胱癌生物学行为的一项有用的指标。 Objective:To evaluate the clinical significance of serum CA19-9 as a tumor marker in patients with advanced bladder cancer. Methods: F'rom Jan 2006 to May 2009, 41 patients with advanced transitional celt carcinoma had preoperative CA19-9 serum assays performed. The association between the serum level of CA19-9 and clinical features were studied. Results:The serum CA19-9 level in 41 patients was(77.1± 194.3)IU/ml and the positive rate was 46.3%(19/41). The serum level in superficial cancer group was( 13.6±5.2)IU/ml and the posi- tive rate was 0%. The level and positive rate were significantly higher in the advanced bladder group in comparison to the superficial cancer group (P〈0. 01). The positive rate of CA19-9 in 11 eases which proved regional lymph node metastasis after operation was 54.5 %,There was significant difference between the presence and absence of lymph node metastasis groups(P〈0. 05). Distant metastasis was found in the lung in 2 cases, the liver,in 3 cases and the distance lymph node in 1 case. The positive rate of CA19-9 was 83. 3% in this group. The 3-year survival rate of CA19-9 positive group and negative group was 52.1%, 85.9% ,respectively, there was significant differ- ence between two groups (P= 0. 036). Conclusions: Increased CA19-9 is more commonly found in patients with lymph node positive or distant metastasis. Prognosis is significantly poor in the patients with elevating serum CA19-9 level. CA19-9 may predict the biological behavior of advanced bladder cancer.
出处 《临床泌尿外科杂志》 北大核心 2010年第11期836-838,共3页 Journal of Clinical Urology
关键词 膀胱肿瘤 CA19-9抗原 移行细胞 bladder cancer CA19-9 antigen transitional cell
  • 相关文献

参考文献13

  • 1Kurokawa K,Kurihara J,Nakata S,et al.The clinical significance of carbohydrate antigen 19-9 (CA19-9) in transitional cell cancer of urinary tract[J].Nippon Hinyokika Gakkai Zasshi,1993,84(6):1074-81.
  • 2Sashide K,Isobe H,Wakumoto Y,et al.CA19-9 as a serum marker for poor prognosis in urothelial carcinoma[J].Urol Int,2004,72(2):112-117.
  • 3Saied G M,EI-Metenawy W H,Elwan M S,et al.Urine carcinoembryonic antigen levels are more useful than serum levels for early detection of Bilharzial and non-Bilharzial urinary bladder carcinoma:observations of 43 Egyptian cases[J].World J Surg Oncol,2007,5:4.
  • 4Noto K,Fujime M,Isobe H,et al.Determination of urinary CA19-9 levels in urothelial cancer-assessment of its role in diagnosis[J].Nippon Hinyokika Gakkai Zasshi,1997,88(3):406-413.
  • 5Chuang C K,Liao S K.Evaluation of CA19-9 as a tumor marker in urothelial malignancy[J].Scand J Urol Nephrol,2004,38(5):359-365.
  • 6萨伊德,杨为民.CA19-9在膀胱癌中的表达及临床意义[J].临床泌尿外科杂志,2008,23(5):341-342. 被引量:2
  • 7Dexeus F,Logothetis C,Hossan E,et al.Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothetial malignancies[J].J Urol,1986,136(2):403-407.
  • 8Iles R K,Jenkins B J,Oliver R T,et al.Beta human chorionic gonadotrophin in serum and urine.A marker for metastatic urothelial cancer[J].Br J Urol,1989,64(3):241-244.
  • 9Izes J K,Dyer M W,Callum M G,et al.CA125 as a marker of tumor activity in advanced urothelial malignancy[J].J Urol,2001,165:1908-1913.
  • 10杨进益,王钢,刘建光,胡小琦,叶林,周杰,姜洪波,姜兴金.晚期转移性膀胱癌患者血清CA125检测的临床意义[J].中华泌尿外科杂志,2007,28(4):257-259. 被引量:4

二级参考文献11

  • 1Madersbacher S, Hochreiter W, Burkhard H, et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol, 2003,21: 690-695.
  • 2Retz M, Lehmann J, Amann E, et al. Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor. J Urol, 2003,169: 86-89.
  • 3Hogdall EV, Hogdall CK,Tingulstad S,et al. Predictive values of serum tumor markers tetranectin OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer,2000,89 : 519-523.
  • 4Guarnaccia S, Pals V, Grous J, et al. Adenocarcinoma of the urachus associated with elevated levels of CA125. J Urol,1991,145:140-141.
  • 5Izes JK, Dyer MW, Callum MG, et al. CA125 as a marker of tumor activity in advanced urothelial malignancy. J Urol, 2001,165 : 1908-1913.
  • 6Langkilde N C, Hastrup J, Olsen S, et al, Immunohis-tochemistry and cytochemistry of experimental rat bladder cancer: brinding of the lectins PNA and WGA and of a Le(Y) mouse monoclonal antibody[J]. J Urol, 1989,141: 981-986.
  • 7Chuanag C K, Liao S K. Evaluation of CA19-9 as a tumor marker in urothelial malignancy[J]. Scand J Urol Nephrol,2004,38(5) :359-365.
  • 8Ohtsuka M, Ito H, Kimura F, et al. Results of surgical treatment for intra-hepatic cholangio-carcinoma and clinicopathological factors influencing survival[J]. Br J Surg, 2002,89(12) :1525-1531.
  • 9Schlieman M G, Ho H S, Bold R J, Utility of tumor markers indetermining respectability of pancreatic caner[J]. Arch Surg , 2003,138(9):951-955.
  • 10Schlieman M G, Ho H S, Bold R J, Utility of tumor markers indetermining respectability of pancreatic caner[J]. discussion 955-956.

共引文献4

同被引文献70

  • 1Chao Xu Zheng~1 Wen Hua Zhan~1 Ji Zong Zhao~2 Dong Zheng~3 Dong Ping Wang~1 Yu Long He~1 Zhang Qing Zheng~1 ~1Department of General Surgery,~2Laboratory of Surgery,~3Department of Medicine,First Affiliated Hospital,Sun Yat-Sen University of Medical Sciences,Guangzhou 510080,Guangdong Province,ChinaDr.Chao Xu Zheng now working as a surgeon and lecturer in the Department of General Surgery,First Affiliated Hospital,Sun Yat-Sen University of Medical Sciences,who is a Ph.D.student,having 7 papers published..The prognostic value of preoperative serum levels of CEA,CA19-9 and CA72-4 in patients with colorectal cancer[J].World Journal of Gastroenterology,2001,7(3):431-434. 被引量:25
  • 2何朝宏,肖传国,杜茂信.尿核基质蛋白22在膀胱癌术后复发监测中的应用[J].临床泌尿外科杂志,2005,20(2):107-108. 被引量:3
  • 3车至香,井娜,王长印,董振芳.超敏C反应蛋白测定在恶性肿瘤诊断中的意义[J].中国现代医学杂志,2006,16(16):2523-2525. 被引量:18
  • 4杨进益,王钢,刘建光,胡小琦,叶林,周杰,姜洪波,姜兴金.晚期转移性膀胱癌患者血清CA125检测的临床意义[J].中华泌尿外科杂志,2007,28(4):257-259. 被引量:4
  • 5Senga Y, Kimura G, Hattori T, et al. Clinical evaluation of solu- ble eytokeratin 19 fragments (cyfra21-1) in senam and urine of pa- tients with bladder cancer [J]. Urology, 1996, 48 : 703-710.
  • 6Moll R, Franke WW, Schiller DL, et al. The catalog of human cy- tokeratins: patterns of expression in m~rmal epithelia, tumors and cultured cells [J]. Cell, 1952, 31: 11-24.
  • 7Niels R, Bukhard B, Michael S, et al. Prognotic impact of CYFRA21-1 and other serum markers in completely resected non-small cell lung cancer [ J]. Lung Cancer, 2002, 36: 256-270.
  • 8Fatela-Cantillo D, Fernandez-Suarez A, Menandez V, et al. Low utility of CYFRA21-1 serum levels for diagnosis and follow up in bladder cancer patients [J]. J Ciin Lab Anal, 2005, 19: 167- 171.
  • 9Suyama T, Nakajima K, Kanhe S, et al. Prognostic: significance of preoperative serum CYFRA21-1 in patients with upper urothelial carcinoma [J]. Int Urol, 2011, 18: 43-44.
  • 10Martin B ,Tatiana B ,Ahmad S ,et al. Current concepts in biomarker technology for bladder cancers [ J ]. Clin Chem,2000,46 (5) :595.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部